Magoha G A
Department of Surgery, College of Health Sciences, University of Nairobi, Kenya.
East Afr Med J. 2000 Feb;77(2):76-9. doi: 10.4314/eamj.v77i2.46398.
To evaluate the effectiveness of sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi.
Prospective open label extension study.
Urology clinics at the Nairobi Hospital, Kenyatta National Hospital and the author's private clinic in Hurlingham, Nairobi.
Two hundred and nineteen adult male patients with erectile dysfunction.
The age range was 33-80 years with a mean of 62.5 years and a peak incidence in the 60-69 year age group. One hundred and nineteen patients (54.34%) had organic causes, 85 patients (38.81%) had psychogenic causes and 15 patients had mixed causes. Two hundred patients (91.32%) had improved sexual function after treatment with viagra. This improvement was sustained during the study period of sixteen weeks and included improved erectile and orgasmic functions and overall sexual satisfaction. One hundred and fifty seven of these patients responded to therapy with 50 mg of viagra; 40 patients with 25 mg and three patients with 100 mg of therapy. Nineteen patients (8.68%) had no improvement in sexual function after viagra administration. Seven patients (3.2%) had adverse effects which were mild and transient. They included mild headaches in three patients, mild dyspepsia in two patients and facial flushing and nausea and vomiting in one patient, respectively.
Oral sildenafil (Viagra) is an effective well tolerated and simple treatment for male erectile dysfunction in the majority of cases. The cost of treatment at about ten United States dollars for the 50 mg tablet is prohibitive and may limit its wide use by many deserving patients in this locality.
评估西地那非（万艾可）治疗内罗毕男性勃起功能障碍的有效性。
前瞻性开放标签扩展研究。
内罗毕医院、肯雅塔国家医院的泌尿外科诊所以及作者在内罗毕赫林厄姆的私人诊所。
219名成年勃起功能障碍男性患者。
年龄范围为33 - 80岁，平均年龄62.5岁，60 - 69岁年龄组发病率最高。119名患者（54.34%）有器质性病因，85名患者（38.81%）有心理性病因，15名患者有混合性病因。200名患者（91.32%）在服用万艾可治疗后性功能得到改善。这种改善在为期16周的研究期间持续存在，包括勃起功能、性高潮功能及总体性满意度的提高。其中157名患者对50毫克万艾可治疗有反应；40名患者对25毫克治疗有反应，3名患者对100毫克治疗有反应。19名患者（8.68%）在服用万艾可后性功能未改善。7名患者（3.2%）出现不良反应，均为轻度且短暂。其中3名患者出现轻度头痛，2名患者出现轻度消化不良，1名患者分别出现面部潮红、恶心和呕吐。
口服西地那非（万艾可）在大多数情况下是一种有效、耐受性良好且简单的男性勃起功能障碍治疗方法。50毫克片剂的治疗费用约为10美元，价格过高，可能会限制该地区许多有需求的患者广泛使用。
